

Ray S Mcdermott

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6679398/publications.pdf>

Version: 2024-02-01

69
papers

9,084
citations

201385

27
h-index

98622

67
g-index

69
all docs

69
docs citations

69
times ranked

12164
citing authors

#	ARTICLE	IF	CITATIONS
1	Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP) Tj ETQq1 1 0.784314 rgBT /Over bo 837-846.	0.8	29
2	Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2022, 186, 631-643.	1.9	55
3	Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2â€‰%—â€‰%2 factorial design. <i>Lancet, The</i> , 2022, 399, 1695-1707.	6.3	261
4	Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. <i>Oncologist</i> , 2022, , .	1.9	18
5	Associations Among Physical Activity, Skeletal Related Events, and Patient Reported Outcomes in Patients with Bone Metastases. <i>Seminars in Oncology Nursing</i> , 2022, 38, 151274.	0.7	4
6	The SARS-CoV-2 Pandemic and Cancer Trials Ireland: Impact, Resolution and Legacy. <i>Cancers</i> , 2022, 14, 2247.	1.7	6
7	2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial. <i>Acta OncolÃ³gica</i> , 2022, 61, 963-971.	0.8	1
8	Diagnostic Strategies for Treatment Selection in Advanced Prostate Cancer. <i>Diagnostics</i> , 2021, 11, 345.	1.3	14
9	Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. <i>European Urology</i> , 2021, 79, 334-338.	0.9	39
10	Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer â€œPantHERâ€œ. <i>Cancers</i> , 2021, 13, 1225.	1.7	8
11	Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 2102-2114.	13.9	427
12	Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2021, 22, 931-945.	5.1	337
13	Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer. <i>Clinical Epigenetics</i> , 2021, 13, 168.	1.8	14
14	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. <i>European Urology</i> , 2021, 80, 275-279.	0.9	28
15	Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21). <i>Cancers</i> , 2021, 13, 4690.	1.7	11
16	Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. <i>Clinical Cancer Research</i> , 2021, 27, 6677-6686.	3.2	12
17	A Multicenter Retrospective Review of Systemic Anti-Cancer Treatment and Palliative Care Provided to Solid Tumor Oncology Patients in the 12 Weeks Preceding Death in Ireland. <i>American Journal of Hospice and Palliative Medicine</i> , 2021, 38, 1404-1408.	0.8	3
18	Pathogenic BRCA Variants as Biomarkers for Risk in Prostate Cancer. <i>Cancers</i> , 2021, 13, 5697.	1.7	10

#	ARTICLE	IF	CITATIONS
19	hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro. <i>Cancers</i> , 2021, 13, 6383.	1.7	3
20	Understanding and Attitudes toward Cancer Clinical Trials among Patients with a Cancer Diagnosis: National Study through Cancer Trials Ireland. <i>Cancers</i> , 2020, 12, 1921.	1.7	4
21	Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene Alteration. <i>Journal of Clinical Oncology</i> , 2020, 38, 3763-3772.	0.8	448
22	The challenge of primary gastric melanoma: a systematic review. <i>Melanoma Management</i> , 2020, 7, MMT51.	0.1	9
23	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. <i>Lancet Oncology</i> , The, 2020, 21, 531-540.	5.1	608
24	The "Good Friday Agreement" and cancer research on the island of Ireland: Evidence for the impact of a tripartite cancer research partnership. <i>European Journal of Cancer</i> , 2020, 129, 15-22.	1.3	6
25	Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 962.	1.8	12
26	Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2487-2496.	3.2	273
27	Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trial. <i>PLoS ONE</i> , 2020, 15, e0243928.	1.1	13
28	Dysphagia Prevalence and Predictors in Cancers Outside the Head, Neck, and Upper Gastrointestinal Tract. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 949-958.e2.	0.6	18
29	Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 931-939.	1.3	48
30	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 121-131.	13.9	982
31	Treatment completion, treatment compliance and outcomes of old and very old patients treated by dose adapted stereotactic ablative radiotherapy (SABR) for T1-T3N0M0 non-small cell lung cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 442-448.	0.5	4
32	Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP) Tj ETQq0 0 0.rgBT /Overlock 10 T LBA2-LBA2.	0.8	6
33	The effect of a structured exercise intervention on CTCs and platelet cloaking in patients with metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 243-243.	0.8	2
34	Immunotherapy-induced endocrinopathies: A multi-center experience.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14251-e14251.	0.8	0
35	Cost effectiveness of updated laboratory monitoring schedule for immunotherapy regimens.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18363-e18363.	0.8	0
36	A randomized trial of exercise on quality of life in men with metastatic prostate cancer: The ExPeCT Trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 97-97.	0.8	9

#	ARTICLE	IF	CITATIONS
37	Carcinogenesis in prostate cancer: The role of long non-coding RNAs. <i>Non-coding RNA Research</i> , 2018, 3, 29-38.	2.4	33
38	Multivisceral Resection for Locally Invasive Colorectal Liver Metastases: Outcomes of a Matched Cohort Analysis. <i>Digestive Surgery</i> , 2018, 35, 514-519.	0.6	6
39	Individualized dosing with axitinib: rationale and practical guidance. <i>Future Oncology</i> , 2018, 14, 861-875.	1.1	15
40	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 773-779.	0.8	1,525
41	RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer-From Cell Line Models to Liquid Biopsies. <i>Diagnostics</i> , 2018, 8, 60.	1.3	15
42	Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours. <i>BMC Cancer</i> , 2018, 18, 854.	1.1	7
43	Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. <i>Cancer</i> , 2018, 124, 3118-3126.	2.0	23
44	Body Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma Treated With Sunitinib. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 47-52.	0.6	82
45	A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience. <i>Hematology</i> , 2017, 22, 341-346.	0.7	5
46	Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer: An International Collaborative Study. <i>Clinical Colorectal Cancer</i> , 2017, 16, 334-342.	1.0	48
47	Therapeutic Potential for FGFR Inhibitors in SOX9-FGFR2 Coexpressing Pancreatic Cancer. <i>Pancreas</i> , 2017, 46, e67-e69.	0.5	4
48	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1182-1191.	5.1	2,058
49	The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 456.	0.7	6
50	Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3916-3923.	0.8	316
51	Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel. <i>Clinical Nutrition ESPEN</i> , 2016, 13, e39-e45.	0.5	81
52	Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach. <i>European Urology</i> , 2015, 68, 891-898.	0.9	91
53	Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. <i>Cancer Medicine</i> , 2014, 3, 1517-1526.	1.3	53
54	Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review. <i>International Journal of Oncology</i> , 2014, 44, 5-16.	1.4	31

#	ARTICLE	IF	CITATIONS
55	Identification of Distinct Phenotypes of Locally Advanced Pancreatic Adenocarcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2013, 44, 73-78.	0.6	1
56	Beyond the Maths of Biology: Long-term Spontaneous Tumoral Regression After Sunitinib Withdrawal. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 198-200.	0.9	1
57	2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 117-124.	5.1	195
58	Fibroblast growth factor receptors, developmental corruption and malignant disease. <i>Carcinogenesis</i> , 2013, 34, 2198-2205.	1.3	122
59	Prognostic role of neutrophil-to-lymphocyte ratio in advanced pancreatic ductal adenocarcinoma: impact of baseline fluctuation and changes during chemotherapy. <i>Tumori</i> , 2013, 99, 516-22.	0.6	12
60	Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes. <i>PLoS ONE</i> , 2012, 7, e50999.	1.1	367
61	RNAi knockdown of Hop (Hsp70/Hsp90 organising protein) decreases invasion via MMP-2 down regulation. <i>Cancer Letters</i> , 2011, 306, 180-189.	3.2	82
62	Sustained response of adenocarcinoma of the urinary bladder to FOLFOX plus bevacizumab. <i>Nature Reviews Urology</i> , 2011, 8, 282-285.	1.9	12
63	Challenges of drug resistance in the management of pancreatic cancer. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1647-1661.	1.1	47
64	The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. <i>European Journal of Cancer</i> , 2010, 46, 2357-2368.	1.3	58
65	A Case of Metastatic Renal Cell Cancer Presenting as Jaundice. <i>World Journal of Oncology</i> , 2010, 1, 218-220.	0.6	5
66	Metastatic Phyllodes Tumor Causing Small-Bowel Obstruction. <i>Clinical Breast Cancer</i> , 2009, 9, 193-195.	1.1	11
67	Reproduction of Langerin/CD207 Traffic and Birbeck Granule Formation in a Human Cell Line Model. <i>Journal of Investigative Dermatology</i> , 2004, 123, 72-77.	0.3	35
68	Cored Tubules are Present in Human Epidermal Langerhans Cells. <i>Journal of Investigative Dermatology</i> , 2003, 120, 407-410.	0.3	4
69	Gene Therapy Applications to Cancer Treatment. <i>Journal of Biomedicine and Biotechnology</i> , 2003, 2003, 35-47.	3.0	11